Deciphering the Effects and Mechanisms of Yi-Fei-San-Jie-pill on Non-Small Cell Lung Cancer With Integrating Network Target Analysis and Experimental Validation

Hongxing Yang1†, Qiuyan Guo2†, Jianbin Wu1, Lixia Zhong1, Lingling Sun1, Wei Liu1, Jigang Wang1,2,3,4 and Lizhu Lin1†

1Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China, 2Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China, 3Central People's Hospital of Zhanjiang, Zhanjiang, China, 4Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, China

Non-small cell lung cancer (NSCLC), which accounts for 85% of lung cancer cases, calls for better therapy. Yi-Fei-San-Jie-pill (YFSJ), a well-applicated traditional Chinese medicine formula, was reported to be effective in the treatment of NSCLC. However, its anti-tumor mechanism still needs to be fully elucidated. Herein, a reliable preclinical orthotopic but not subcutaneous model of NSCLC in mice was established to evaluate the anti-cancer properties and further validate the mechanisms of YFSJ. A bioinformatic analysis was executed to identify the potential targets and key pathways of YFSJ on NSCLC. In detail, the anti-tumor effect of YFSJ and the autophagy inhibitor 3-MA was evaluated according to the tumor fluorescence value and comparison of different groups’ survival times. As a result, YFSJ markedly decreased tumor size and prolonged survival time in contrast with those in the orthotopic model group (p < 0.05), and it also significantly regulated the protein expression levels of apoptosis- and autophagy-related proteins. In conclusion, this study provides convincing evidence that YFSJ could inhibit the growth of tumors and prolong the survival time of tumor-bearing mice based on the NSCLC orthotopic model, and its anti-tumor effect was closely associated with the promotion of apoptosis and interference of autophagy coupled with regulation of immune infiltration.

Keywords: non-small cell lung cancer, Yi-Fei-San-Jie-pill, orthotopic model, apoptosis, autophagy, immune infiltration

Abbreviations: YFSJ, Yi-Fei-San-Jie(-pill); NSCLC, non-small cell lung cancer; 3-MA, 3-methyladenine; TCM, traditional Chinese medicine; LLC, Lewis lung cancer; TCMSp Database, traditional Chinese medicine systems pharmacology database; OMIM Database, Online Mendelian Inheritance in Man Database; KEGG Database, the Kyoto Encyclopedia of Genes and Genomes Database; TTD Database, Therapeutic Target Database; PPI, protein–protein interaction; GO, gene ontology; GO (BP), gene ontology (biological process); GO (CC), gene ontology (cell component); GO (MF), gene ontology (molecular function); TEM, transmission electron microscopy; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TISMO, Tumor Immune Syngeneic Mouse database; TCGA, The Cancer Genome Atlas Database; MIC, immune checkpoint inhibitors; TIMER, tumor immune estimation resource database; GEPIA2, gene expression profiling interactive analysis database, Version 2; EK, Panax (Panax pseudoginseng L. [Araliaceae]; Panax pseudoginseng L.); JC, Jiangcan (Bombyx Batryticatus); LZ, Lingzhi (Ganoderma lucidum); M2, Monoclonal Tumor; MM, Mixed inoculation of Tumor and M2; MZC, Maozhuacao (Ranunculus ternatus Thunb.); SCG, Shancigu (Cerastium appendiculata(D.Don) Makino [Orchidaceae]; Cerastium pseudobulbosa); XYS, Xiangshen (Panax quinquefolius L. [Araliaceae]; Panax quinquefolius L.); ZBM, Zhebeimu (Fritillaria thunbergii Miq. [Liliaceae]; Fritillaria thunbergii bulbus); ZIF, Zhongjiefeng (Sarcandra glabra [Thunb.] Nakai [Chloranthaceae; Sarcandrae herba]); FOX, forkhead box O.
INTRODUCTION

Lung cancer has ranked as the world’s first malignant tumor in recent decades, with non-small cell lung cancer (NSCLC) being the most common pathological type. The 5-year survival rate of NSCLC is merely 15–16% (Tfayli et al., 2021). Chemotherapy and radiotherapy, ranking first-class treatments of NSCLC, however, are prone to cause serious side effects and acquired resistance. While, targeted therapy reaches a potent response and definite effect on NSCLC driven by specific gene mutations, the acquired resistance often appears within 1 year (Hirsch et al., 2016). Therefore, the challenge of drug resistance needs to be solved urgently. Immunotherapy pushes lung cancer treatment into a broad new era and has brought great confidence to patients whereas its objective response rate in NSCLC is not as high as expected, and even about 20% of progressed lung cancer patients have severe side effects such as super-progression (Kim et al., 2019). Hence, it is necessary to control its side effects and improve its response rate. Previous studies (Chang et al., 2013; Lou et al., 2016) have shown that traditional Chinese medicine (TCM) treatment of cancer plays an important role in alleviating the side effects of chemotherapy and radiotherapy, decreasing acquired resistance, improving patients’ life quality, and prolonging survival time. Yi-Fei-San-Jie-pill (YFSJ), a long-time applied formula by our research team targeting replenishing Qi and removing phlegm, has been made into hospital preparation and gained a patent (201710010908.4). Some clinical studies (Zhou DH. et al., 2005; Zhou D. et al., 2005) have demonstrated that YFSJ stabilizes tumors, prolongs survival, and improves the life quality of lung cancer patients, but its anti-cancer mechanisms are still not fully elucidated.

Bioinformatics has played an increasingly important role in the era of multi-omics and has a wide range of applications in the interpretation of complicated diseases such as cancer that are considered a systems disease and the discovery or mechanistic elucidation of drugs (Yildirim et al., 2007). Network pharmacology, a classic methodological example of bioinformatics based on systems biology (Hopkins, 2007), has strong explanatory power in the demonstration of TCM pharmacology. The commonly used methods of network pharmacology include CIPHER, DMIM network pharmacology algorithm, etc. (Li and Zhang, 2013). Given that there have been successful cases of network pharmacology in the discovery of kinds of drugs (Hopkins, 2008) and the reverse of side effects (Brown et al., 2015), and this study was based on the study of TCM formula. It was rational and necessary to use network pharmacology to explore the potential mechanism of YFSJ and then verifying it with wet experiments, so as to be more convincing in the demonstration of the conclusion (Tang and Aittokallio, 2014). Furthermore, bioinformatics coupled with an orthotopic but not subcutaneous model of lung cancer can be more attractive and enlightening, for the orthotopic model is more faithful to cancer pathology (Weiss et al., 2015). Therefore, bioinformatic investigation coupled with the experimental exploration based on an orthotopic model of lung cancer in mice was performed in this study (Figure 1). The effect of tumor inhibition was evaluated by comparing the fluorescence values captured by using the small animal live imaging instrument, and the survival time of different groups was calculated by the statistical method of survival analysis. The key targets of YFSJ were extracted via the MCC algorithm of the Cytohubba plug-in of Cytoscape and further analyzed via GO enrichment and KEGG enrichment. Apoptosis and autophagy-related proteins were indicated as the most related two biological processes of NSCLC. Western blot was performed to investigate the molecular mechanism based on the bioinformatic analysis results by evaluating the expression levels of the apoptosis-related proteins and the autophagy-related proteins. We discovered that the tumor size of mice that accepted YFSJ for 3 weeks was markedly decreased in contrast with those in the orthotopic model group (p < 0.05). And YFSJ dramatically prolonged the survival time of tumor-bearing mice (p < 0.05). The key targets of YFSJ acting on NSCLC were closely enriched in apoptosis, autophagy, and immune-related biological processes were also implicated in.

MATERIAL

6–8 weeks old SPF-grade female C57BL/6N mice (purchased from Beijing Wei Tong Li Hua Laboratory Animal Technology, SCXK (Beijing) 2016-0006), Matrigel (BD, NO 356234), LLC-luc cells (replenished from Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd. (LZZQ0099)), shaver (Codos, CP-8000), disposable sterile insulin syringe (BD, 328421), disposable sterile syringe (BD, 300841), D-luciferin (Potassium Salt, Gold Bio Technology, LUCK-1G), RIPA (strong) lysis solution (Kangwei Century Biotechnology, CW23335), BCA protein quantification kit (Kangwei Century Biotechnology, CW0014S), skimmed milk powder (Shanghai Biyuntian Biotechnology, P0216-300g), recombinant anti-ATG7 antibody (ab133528-10), recombinant anti-ATG16L1 antibody (ab187671-10), recombinant anti-LC3B antibody (ab192890-10), recombinant anti-SQSTM1/P62 antibody (ab109012-10), recombinant anti-Beclin1 antibody (ab210498-10), recombinant anti-Bcl-xl antibody (ab32370-10), recombinant anti-P53 antibody (ab246550-10), recombinant anti-PD-L1 antibody (ab213480-10), recombinant anti-F4/80 antibody (30325T, CST), anti-GAPDH polyclonal antibody (K106389P, Solarbio), recombinant anti-Bcl-2 antibody (ab182858-10), anti-β-actin (Beijing Solarbio Technology, K101527P-100), and goat anti-rabbit IgG-HRP (Beijing Solarbio Technology, SE134-0.1).

METHOD

LLC-luc Cell and A549 Culture

LLC-luc cells are mouse LLC cells labeled with luciferase, culturing with DMEM containing 10% fetal bovine serum and 1% penicillin and streptomycin and were maintained in a 5% CO2 incubator at 37°C. Passaging in 100 mm diameter dishes once every 3 days. A549 cells are human lung cancer cells and are cultured with 1,640, while the other conditions are the same as for LLC-luc cells.
Orthotopic Model
Taking LLC-luc cells in logarithmic growth phase, then digested the cells with 0.25% trypsin, washed and resuspended the cells with PBS, adjusted to 2×10^7 cells/ml cell suspension, and added matrigel pre-chilled on ice at a volume ratio of 1:1, gently blow evenly and then place on ice for later use. After intraperitoneal injection of 2% pentobarbital sodium solution with 0.3 ml per 100g bodyweight of every mouse to anesthetize the mice. Lying
them on the right side, the left armpit of the mice was shaved and disinfected with 75% ethanol along the left anterior axillary line for 1.5 cm up from the upper edge of the left costal arch to make a 5 mm incision (Wang et al., 2018), separating the skin and subcutaneous tissue, and the chest wall was exposed. When the pink lung lobe could be seen, a needle was vertically inserted into the left lung at a 4 mm depth, and the cell suspension was slowly injected into the left lung. Then, stopped the needle for 20 s to solidify the matrigel and slowly pulled out the needle with another hand pressing the inserted needle with a cotton swab to prevent the cell suspension from leaking. Then, sutured the incision with 1–2 stitches after removing the needle.

Drug Preparation and Administration

The composition of YFSJ, a typical hospital preparation, is shown in Table 1 and its production process was standardized and documented in a patent (NO.201710010908.4). Briefly, primary botanical drugs of *Panax quinquefolius* L. [Araliaceae; *Panaxis quinquefolii* radix], *Fritillaria thunbergii* Miq. [Liliaceae; *Fritillariae thunbergii* bulbus], *Ranunculus ternatus* Thunb. [Ranunculaceae; *Ranunculi ternati* radix], *Sarcandra glabra* (Thunb.) Nakai [Chloranthaceae; *Sarcandraceae* herb], *Crestmastra appendiculata* (D.Don) Makino [Orchidaceae; *Crestmastra pseudobulbus*, *Pleiones pseudobulbus*, *Ranunculus pseudobulbus*], *Fritillaria thunbergii* Miq. [Liliaceae; *Fritillariae thunbergii* bulbus], *Pleiones pseudobulbus*, *Ranunculus ternatus* Thunb. [Ranunculaceae; *Ranunculi ternati* radix], *Cremastra pseudobulbus*, and *Sarcandra glabra* (Thunb.) Nakai with the mass ratio of 10:5:3:4 were decocted three times.

| Botanical plant name | Chinese name | Chinese abbreviation |
|----------------------|--------------|----------------------|
| *Panax quinquefolius* L. | Xi Yang Shen | XYS |
| *Fritillaria thunbergii* Miq. | Zhe Bei Mu | ZBM |
| *Ranunculus ternatus* Thunb. | Mao Zhus Cao | MZC |
| *Sarcandra glabra* (Thunb.) Nakai | Zhong Jie Feng | ZJF |
| *Crestmastra appendiculata* (D.Don) Makino | Shan Ci Gu | SCG |
| *Pinellia ternata* (Thunb.) Makino | Fa Ban Xia | BX |
| *Bombyx batryticatus* | Jiang Can | JC |
| *Ganoderma lucidum* | Ling Zhi | LZ |

The screening condition was oral bioavailability (OB) ≥30% and drug-likeness (DL) ≥0.18. The ingredients of Jiang Can, which cannot be searched out in TCMS, were downloaded from HIT 2.0 (http://hit2.badd-cao.net/) (Ye et al., 2011).

Collection of Known NSCLC-Related Genes

NSCLC-related genes were obtained from Online Mendelian Inheritance in Man (OMIM, https://www.omim.org/) (Amberger et al., 2019), DrugBank database (http://www.drugbank.ca/, version 3) (Wishart et al., 2018), the Kyoto Encyclopedia of Genes and Genomes (KEGG, http://www.genome.jp/kegg/, last updated: 1 October 2021) (Kanehisa and Goto, 2000), DisGeNET (http://www.disgenet.org) (Piñero et al., 2020), GeneCards (https://www.genecards.org/, version 5.7), NCBI (https://www.ncbi.nlm.nih.gov/), PharmGKB (https://www.pharmgkb.org/) (Whirl-Carrillo et al., 2021), and Therapeutic Target Database (TTD, http://db.idrblab.net/tdt/) (Zhou et al., 2021).

Construction of the PPI Network and Extraction of the Subnetwork

The PPI network was constructed on the basis of the public database STRING (Search Tool for Known and Predicted Protein–Protein Interactions, version 11.5, https://cn.string-db.org/) (Szklarczyk et al., 2019), with network display options hiding disconnected nodes in the network and the combined score higher than the highest confidence (0.900) of all of the
combined scores. Then the interaction networks were visualized by Cytoscape software (https://cytoscape.org/, version 3.8.0) (Shannon et al., 2003). A node was defined as a gene in the network, and an edge was defined as the interaction between two genes. Hub genes were defined as nodes of topological importance and extracted via the Cytohubba (Chin et al., 2014) plug-in by the MCC algorithm (Chin et al., 2014) for further investigation.

Enrichment Analysis of Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes

Enrichment analyses of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were performed based on the Database for Annotation, Visualization, and Integrated Discovery (Metascape, https://metascape.org/gp/index.html#/main/step1, database last update date: 2022-01-01) (Zhou et al., 2019). Only GO (Biological Processes, BP), GO (Cellular Components, CC), GO (Molecular Functions, MF) and KEGG pathways with p-values less than 0.01 (corrected using the Bonferroni method (Armstrong et al., 2014)) were selected and visualized by the tool “Barplot Gradient” in Hiplot (https://hiplot.com.cn) (Li et al., 2022).

Live Imaging of Mouse Tumor

According to the results of preliminary experiments, lung tumors can be detected with the small animal live imaging instrument (IVIS lumina Series III) on the 4th day after injecting. Intraperitoneally injecting the luciferase substrate solution of 15 mg/ml with PBS for 150 ul/mouse, then putting the mice into the isoflurane anesthesia box quickly and taking images in a supine position in the small animal live imaging instrument with an exposure time of 10 s, and saving the pictures to calculate the fluorescence value.

Western Blot

After the mice were sacrificed, the tumors were quickly stripped and collected, and 100 mg of tumor tissue was cut out (the same weight as normal lung tissue from the control group). A RIPA (strong) lysis solution containing 1% protease inhibitor was added to grind and lyse for 30 min, then centrifuged at 12,000 r·min⁻¹, took the supernatant and quantified it with the BCA kit, and performed electrophoresis, transferring membrane, and blocking. After preparing the primary antibody with 5% skim milk, it was incubated overnight. Then washed the membrane with TBST, incubated the secondary antibody for 1 h, washed the membrane, and performed exposure.

Transmission Electron Microscopy

A549 cells were pretreated with glutaraldehyde for observation of mitochondrial morphology. Cells were cut up and fixed with glutaraldehyde (4%) and then with 1% osmium tetroxide. Then the cells were dehydrated in graded ethanol and embedded in Epon. Then cell sections were preconditioned by special TEM staff before TEM observation (Hitachi H7500, Tokyo, Japan).

Query of the Correlation of Hub Genes With Immune Infiltration, Together With Survival Outcome

The investigation/inquiry of the 15 hub genes’ roles within the immunological process was performed in the TISMO database (Zeng et al., 2021) and the correlation of hub genes with immune infiltration, together with survival outcome in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) from TCGA, was investigated in TIMER (Li et al., 2017) and GEPIA2 (Tang et al., 2019) databases.

Statistical Analysis

GraphPad Prism 9.0.0 (GraphPad Software, CA, United States) was used to perform a one-way analysis of variance and survival curve test in the experimental results of this study. The statistical results were expressed as X ± S. The statistical differences between groups were analyzed by one-way analysis of variance and t test. The difference of p < 0.05 is statistically different, and p < 0.01 indicates that the difference is markedly different.

RESULTS

Yi-Fei-San-Jie-pill Inhibited Tumor Growth and Prolonged Survival Time in Orthotopic Lung Cancer Model of Mice

As shown in Figure 2A, small animal live imaging was performed on mice at different time points, including before drug administration and 1, 2, and 3 weeks after administration. The fluorescence of lung cancer in the Model group increased dramatically, and the enhancing trend was the most significant; while, the fluorescence values of the YFSJ group and 3-MA group were ambiguous with time, but the enhancing trends were remarkably lower than that of the Model group, and YFSJ group exhibited reduction with a statistical difference (p < 0.05) after 3 weeks of administration. Additionally, the enhancing trend of the 3-MA group seems more stable than that of the YFSJ (Figure 2B). Figure 2C suggests that YFSJ prolonged the survival time of tumor-bearing mice, sharing the same effect as 3-MA. Nevertheless, 3 mice in the Model group died successively within 3 weeks, but there was no death in the YFSJ and 3-MA groups (p < 0.05). Taken together, it shows that YFSJ inhibited tumor growth and prolonged survival time in the orthotopic lung cancer Model.

The Collection of All NSCLC Related Genes

All the NSCLC related genes were collected from as many comprehensive databases as possible and the intersection between chemical constituent targets of YFSJ and NSCLC-related genes was displayed by the Venn diagram (Chen et al., 2021). As shown in Figures 3A, 8 databases were searched for NSCLC-related genes, and a total of 6,981 genes (provided in Supplementary Data Table S1) were fully collected. YFSJ targets share 182 genes with NSCLC-
related genes (Figure 3B), which accounts for a considerable extent of YFSJ targets.

The Construction of Chemical Constituent Targets of Yi-Fei-San-Jie-pill and NSCLC-Related Genes Network

As shown in Figure 4, YFSJ contains 8 botanical drugs (the central yellow nodes of 8 circles, provided in Supplementary Table S2), and 69 chemical constituents collected in total were represented by the circular nodes (see their standard names in Supplementary Table S3). The rectangle nodes signal 182 target genes (the symbol lists are displayed in Supplementary Table S4). A1 represented stigmasterol and was shared within *Pinellia ternata* (Thunb.) Makino [Araceae; *Pinelliae rhizoma praeparatum*], *Ranunculus ternatus* Thunb. [Ranunculaceae; *ranunculi ternati radix*], and *Cremastra appendiculata* (D.Don) Makino [Orchidaceae; *cremastrae pseudobulbus, pleiones pseudobulbus*]. Additionally, quercetin (ZJF9) and anhydroicaritin (ZJF2) in *Sarcandra glabra* (Thunb.) Nakai [Chloranthaceae; *Sarcandras herba*], cavidine (BX2), baicalein (BX3) and coniferin (BX6) in *Pinellia ternata* (Thunb.) Makino [Araceae; *Pinelliae rhizoma praeparatum*], and 2-methoxy-9,10-dihydrophenanthrene-4,5-diol (SCG1) of *Cremastra appendiculata* (D.Don) Makino [Orchidaceae; *Cremastrae pseudobulbus, Pleiones pseudobulbus*] were also accounted for critical proportion.

PPI Network Construction and Hub Genes Extraction

The 182 intersectional genes were searched in STRING for PPI network construction. As shown in Supplementary Figure S1A,
the PPI network contains 181 nodes and 728 edges. The average node degree is 8.04, and the average local clustering coefficient is 0.419; the PPI enrichment p-value being less than 1.0e-16. The Cytohubba plug-in was employed to extract hub genes via the MCC algorithm. The hub genes subnetwork (Supplementary Figure S1B) contains 15 top genes (Table 2): interleukin 1 beta (IL1B), C-X-C motif chemokine ligand 8 (CXCL8), interleukin 6 (IL6), tumor necrosis factor (TNF), interleukin 1 alpha (IL1A), BHLH transcription factor (MYC), NF-KB subunit (RELA), jun proto-oncogene, AP-1 transcription factor subunit (JUN), C-C motif chemokine ligand 2 (CCL2), hypoxia-inducible factor 1 subunit alpha (HIF1A), mitogen-activated protein kinase 1 (MAPK1), fos proto-oncogene, AP-1 transcription factor subunit (FOS), cyclin D1 (CCND1), tumor protein p53 (TP53), and estrogen receptor 1 (ESR1). It is speculated that the 15 top genes may play pivotal roles in ameliorating the lung tumor effect of YFSJ.

**Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes Enrichment of Yi-Fei-San-Jie-pill’s Inhibitive Effect on Lung Tumor**

Both GO and KEGG enrichment of 15 hub genes were performed in the Metascape database for details of YFSJ’s inhibitive effect on lung tumor. As exhibited in Figure 5A, the 15 top genes were enriched mainly in BP of response to cytokines, positive regulation of pre-miRNA transcription by RNA polymerase II, cellular response to interleukin-1, negative regulation of cell population proliferation, cellular response to tumor necrosis factor, regulation of apoptotic signaling pathway, and response to wounding which were highlighted by red boxes and the same went for the following. While, CC of the transcription regulator complex and MF of cytokine activity were primarily enriched. Also, the KEGG enrichment (Figure 5B) suggests that the 15 top genes mainly affect the AGE-RAGE signaling pathway in diabetic complications (sub-pathways like TNF signaling pathway, MAPK signaling pathway, NF-kB signaling pathway, and necroptosis), Kaposi sarcoma-associated herpesvirus infection (sub-pathways like pathways in cancer and cellular senescence), Th17 cell differentiation (sub-pathways like apoptosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, B-cell receptor signaling pathway, HIF-1 signaling pathway, and estrogen signaling pathway), proteoglycans in cancer, mitophagy, and chemokine signaling pathway. Taken together, the enrichments mentioned earlier imply that fundamental biological processes such as apoptosis, au (mi) tophagy, cancer-related pathway, cytokine/immune-related pathway, and miRNA biological process might be involved in the anti-tumor impact of YFSJ.

**Yi-Fei-San-Jie-pill Was Verified to Inhibit the Expression of Apoptosis-Related Proteins and Autophagic Proteins and to Interfere With Mitophagy**

The anti-apoptosis proteins Bcl-2 and Bcl-xl in the Model group were increased compared with those in the control group (Figures 6A,H,I), especially Bcl-2 which significantly increased (Figure 6H), indicating that the tumor cells gained anti-apoptotic ability remarkably. YFSJ significantly reduced the expression of
Bcl-2 (Figure 6H) and Bcl-xl proteins (Figure 6I). Meanwhile, compared with the Model group, 3-MA reduced the expression of Bcl-2 in tumor-bearing mice, but there was no statistical difference (Figure 6H); while 3-MA remarkably increased the expression of Bcl-xl (Figure 6I), which was the same as that of the YFSJ group. The effect of Bcl-xl protein expression was the opposite, suggesting that 3-MA had no obvious effect on the apoptosis mechanism. P53, the well-known anti-apoptosis protein, was significantly upregulated in the YFSJ and 3-MA groups (Figures 6A,G). In addition, autophagy proteins in the Model group were generally upregulated compared with those in the Control group, suggesting that autophagy in tumor cells was generally enhanced. YFSJ remarkably reduced Atg16 (Figures 6B,K), Atg7 (Figures 6B,J) and LC3-2/LC3-1 ratio (Figures 6C,N), significantly increasing the expression of P62 (Figures 6B,L), suggesting that YFSJ remarkably inhibited tumor autophagic activities and subsequently blocked autophagy flow, which was shown by the accumulation of P62. 3-MA also significantly inhibited the expression of Atg7 (Figures 6B,J) and increased the expression of P62 (Figures 6B,L), which was more obvious than that of the YFSJ group, but Atg16 (Figures 6B,K) and LC3-2/LC3-1 ratio (Figures 6C,N) were remarkably higher than that in the Model group, suggesting that 3-MA may mainly target to Atg7 and its downstream pathways specifically to interfere with autophagy. Both 3-MA and YFSJ did not significantly inhibit Beclin1 protein expression (Figures 6C,M), which, however, was even upregulated by YFSJ, suggesting that the regulation of autophagy by both 3-MA and YFSJ is Beclin1-independent in the mouse orthotopic lung cancer Model of this study. According to the mitophagy pathway of the enrichment from 15 top genes, we detected the A549 cell transmission electron microscope after YFSJ administration.
TABLE 2 | Top 15 genes extracted from PPI ranked by the MCC algorithm.

| Rank | Name      | Score  |
|------|-----------|--------|
| 1    | JUN       | 19,600 |
| 2    | RELA      | 18,582 |
| 3    | TNF       | 12,622 |
| 4    | MYC       | 12,246 |
| 5    | IL6       | 11,772 |
| 6    | ESR1      | 11,412 |
| 7    | IL1A      | 10,808 |
| 8    | CCL2      | 10,800 |
| 9    | IL1B      | 10,360 |
| 10   | CXCL8     | 10,206 |
| 11   | FOS       | 8,806  |
| 12   | HIF1A     | 8,788  |
| 13   | CCND1     | 7,786  |
| 14   | TP53      | 7,100  |
| 15   | MAPK1     | 6,177  |

The meaning of the italic values represents the scores that were calculated using the MCC algorithm to evaluate the relationship between nodes and edges. The higher the score, the more important the gene is.

Figure 6D is the Control group, and Figures 6E,F are the YFSJ group, which shows that YFSJ interfered with mitophagy.

**Immune Search of Preclinical Lung Cancer Model Together With The Correlation of Hub Genes With Immune Infiltration**

The LLC mouse Model was widely applied in cancer research, and the TISMO database was established (Zeng et al., 2021) because of the oncology immunotherapy burst. The enrichment of 15 hub genes implied that YFSJ might inhibit orthotopic lung tumors via immune-related targets or pathways. Further inquiry of the 15 hub genes’ roles within the immunological process was performed in the TISMO database and IL1A (Figure 7A) and IL1B (Figure 7B) were expressed higher in non-responders than in baseline in LLC mice Model treated with anti-CTLA4 and anti-PD1, which indicated that IL1A and IL1B may be the factors that blunted the effect of immune checkpoint inhibitors (ICI). While, ESR1 displayed the opposite trend (Figure 7C) and implied a positive role in ICI treatment. It was obvious that IL1A, IL1B, and ESR1 may have played important roles in the immunotherapy of the LLC mice Model. To date, most pre-clinical mice models have been subcutaneous, which, however, inevitably differ from orthotopic models, especially in the immunological process. Hence, we detected the markers of macrophage (F4/80) and classic immune checkpoint PD-L1. As shown in Figure 7D, F4/80 and PD-L1 expression were higher in the orthotopic model than in the subcutaneous model, which explicitly indicated that the immune process (e.g., innate immune) was far more fully involved in orthotopic than the subcutaneous model. Interestingly, F4/80 was expressed higher in the center than that of the border in the subcutaneous model, while, conversely, PD-L1 was lower in the center than that of the border in this model. The inquiry of hub genes was also performed in TCGA via TIMER and the correlation between the genes of CCL2 (Figures 8A,B), MAPK1 (Figure 8C), IL1B (Figures 8D,E), ESR1 (Figure 8F), HIF1A (Figure 8G), IL1A (Figure 8H), and different immune cells (e.g., neutrophil, dendritic cell, and macrophage that belong to innate immune) infiltrated in lung adenocarcinoma (LUAD) and/or lung squamous cell carcinoma (LUSC) was positively significant. Whereas, the correlation of genes and purity of infiltration level displayed negative significant. Taken together, these outcomes hinted that it might be innate immune that accounted for immunological process involved in YFSJ targeting lung cancer.

**Immune Related Survival of Hub Genes Investigation**

Kaplan–Meier plots for immune infiltrates of lung adenocarcinoma (LUAD) and/or lung squamous cell carcinoma (LUSC) from TCGA and MAPK1, IL1A, IL1B, CCL2, HIF1A, and ESR1 from 15 hub genes were also performed in TIMER and as shown in Figure 9, B cell and Dendritic cell (DC) in LUAD (Figure 9A) and MAPK1 in LUAD (Figure 9B), IL1A (Figure 9C) and IL1B (Figure 9D) with DC, HIF1A (Figure 9G) and CCL2 with B cell and DC in LUSC (Figure 9E). CCL2 (Figure 9F), and ESR1 (Figure 9H) in LUSC indicated the survival differences, which hinted that MAPK1, IL1A, IL1B, CCL2, HIF1A, and ESR1 might potentially serve as prognostic signatures together with B cell or dendritic cell. The survival map of 15 hub genes in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) from TCGA was investigated in GEPIA2, and as Supplementary Figure S2 showed that in LUSC, ESR1 and CCL2 are significantly positive in the hazard ratio (HR). While in LUAD, CCND1, MAPK1, HIF1A, and RELA are significantly positive in HR. Taken together, the survival map confirmed that ESR1, CCL2, MAPK1, and HIF1A may predict a poor prognosis of NSCLC.

**DISCUSSION**

Although new therapies are emerging continuously, there is still a lack of better therapies with higher response rates and fewer side effects for NSCLC. TCM has a long history of treating lung cancer with definite effects and fewer side effects and can promote the survival of patients (Teng et al., 2020), which is worthy of in-depth illustration. Based on TCM theory, the pivotal pathogenesis of NSCLC is the weakness of Qi with phlegm and blood stasis, which plays a fundamental role throughout the oncogenic and progressive process of NSCLC (Wang et al., 2021). Weakness of Qi is the primary cause of tumors and blood stasis in the subsequent course. YFSJ, directed against the basis of the TCM theory of “phlegm, blood stasis, poison and deficiency” for NSCLC, consisting of Panax quinquefolius L. [Araliaceae; Panaxis quinquefolii radix], Ganoderma lucidum, Fritillaria thunbergii Miq. [Liliaceae; Fritillariae thunbergii bulbis], Cremastrum appendiculatum (D.Don) Makino [Orchidaceae; Cremastrae pseudobulbus, Pleiones pseudobulbus], Ranunculus ternatus Thumb. [Ranunculaceae; Ranunculi ternati radix], Sarcordra glabra (Thumb.) Nakai [Chloranthaceae; Sarcordrae herba], Bombyx batryticatus, and Pinellia ternata (Thumb.)
**Makino** [**Araceae; Pinelliae rhizoma praeparatum**] is the basic applicant formula for the treatment of NSCLC in the Cancer Center of the First Affiliated Hospital of Guangzhou University of Chinese Medicine. Prospective randomized controlled clinical trials were performed on nearly 300 patients with stage III and IV NSCLC from 6 hospitals across China, which revealed that the median survival time reached 477 days, maintaining a high quality of life as well as less economic burden (Zhou et al., 2014).

Figure 4 displayed that the nodes connected with more edges of 69 chemical constituents may be the key chemicals in YFSJ that carry out the anti-tumor effects. For example, A1 (Stigmasterol) was the most shared component among different botanical drugs of YFSJ and almost have the most abundant edges with other nodes. Then, ZJF9/2/6, SCG1, XYS6/4, JCI1/3, BX3/2/6, LZ10, ZBM1/3, and MZC1/3 also have more edges than the others. According to TCM theory, YFSJ contains 2 groups of botanical drugs: those reinforcing Qi and nourishing Yin (FuZheng) group and removing phlegm and blood stasis (QuXie) group. The former group includes XYS and LZ, and the latter, the rest of the botanical drugs of YFSJ. Therefore, we concluded that XYS6/4 and LZ10 may be the main components that carry out the "reinforcing Qi and

---

**FIGURE 5 | GO enrichment of 15 top genes extracted from PPI network (A).** BP: biological process, CC: cell component, and MF: molecular function. KEGG enrichment of 15 top genes extracted from PPI network (B). The items marked with red boxes represent the very important GO processes and KEGG pathways that directed to further analysis.
nourishing Yin” function, and ZJF9/2/6, SCG1, JC1/3, BX3/2/6, ZBM1/3, and MZC1/3 may be the core components to remove phlegm and blood stasis. When we searched for the pharmacologic action of these components, the literature showed that XYS6/4 and LZ10 stimulated immune function (Li X. et al., 2020) and exhibited anti-proliferation, anti-
invasion, anti-metastasis effects, and delayed AD progression (Lai et al., 2019), which was consistent with the design that XYS and LZ were targeted for strengthening Qi and with the pathophysiology that weakness of Qi was primary cause of NSCLC.

As to removing phlegm and blood stasis (QuXie) group, ZJF9 (quercetin) was reported to reduce Bcl-2 and enhance apoptosis in NSCLC (Alam et al., 2022), inhibit the proliferation and metastasis of NSCLC via the Fn14/NF-κB pathway (Dong et al., 2020), which was in accordance with the inhibiting Bcl-2 of YFSJ in the present study. JC1 (beta-carotene) was reported to inhibit the activation of MAPK in the ferret lung cancer model (Kim et al., 2006), and this echoes back that MAPK1 predicts the prognosis in Figure 8D. BX3 (baicalein) was reported to induce mitochondrial fission, apoptosis and regulate autophagy in an LLC xenograft model (Deng et al., 2020), inhibit NSCLC invasion and metastasis by regulating the inflammation microenvironment (Zhang J et al., 2020), which agrees with the conclusion of the present study that apoptosis, autophagy and even the inflammation-related factors that 15 hub genes containing played a significant role in YFSJ’s inhibitive effect of NSCLC. At present, most animal lung cancer experiments generally adopt subcutaneous tumor models, which are convenient to operate and have high tumor formation rates. Whereas the subcutaneous tumor model cannot simulate the entirely natural process of tumor initiation, development, and even metastasis in the organs or can reflect the crosstalk between tumor cells and the tumor microenvironment. In addition, given
the perspective of TCM, the lung cancer subcutaneous tumor model does not reflect the onset and progression of the tumor in the lung and lung meridian of TCM, and it deviates tremendously from the lung cancer patients in a real-world setting. Therefore, it is not conducive to the research of TCM based on the theory of visceral outward manifestation and meridian. It is also found that some TCM botanical drugs are effective in orthotopic transplantation of lung cancer model mice, but there is poor or no effect in subcutaneous transplantation model mice (Jacoby et al., 2010), which indicates that the orthotopic cancer model and the subcutaneous cancer model are almost totally different. It was confirmed in the present study that immune checkpoint PD-L1 and F4/80, the marker of macrophages, were detected to express significantly higher in the orthotopic model than in the subcutaneous one. The orthotopic cancer model tends to mimic the process of tumorigenesis, immunoediting, and immune escape of lung cancer in mice, providing a prerequisite for the interpretation of the TCM mechanism and tumor immunotherapy.

In addition, protein–protein interactions are mainly offered by the STRING database according to confidence score, and all protein interaction data were weighted, integrated, and therefore have a reliable calculated value (confidence score), enabling users to screen large-scale target protein networks by simply selecting the confidence score. Since the CytoHubba plug-in was common in hub genes extraction (Ma et al., 2021), we ran it via the MCC algorithm, which was reported to be superior to others in the CytoHubba. The hub genes extracted from the PPI network of YFSJ targets and NSCLC targets intersection have enriched BP (e.g., cellular response to

**FIGURE 8** | The correlation between CCL2 (A,B), MAPK1 (C), IL1B (D,E), ESR1 (F), HIF1A (G), and IL1A (H) from 15 hub genes with different immune cells infiltrated in lung adenocarcinoma (LUAD) and/or lung squamous cell carcinoma (LUSC) from TCGA.
FIGURE 9 | Kaplan-Meier plots for immune infiltrates of lung adenocarcinoma (LUAD) and/or lung squamous cell carcinoma (LUSC) from TCGA (A) and MAPK1 (B), IL1A (C), IL1B (D), CCL2 (E,F), HIF1A (G), and ESR1 (H) from 15 hub genes to visualize the survival differences. Levels are divided into low and high levels by 50% and the red curve represents the high top 50% while the blue curve represents the low bottom 50%. The p-value of the log-rank test for comparing survival curves of two groups is shown in each plot, and p < 0.05 was considered significantly different.
interleukin-1, response to xenobiotic stimulus, and response to wounding) and pathways (Th17 cell differentiation) involved in innate immunity. Innate immunity executes as a fundamentally defensive system and has been exploited for novel immunotherapy of kinds of cancers (Kalafati et al., 2020; Priem et al., 2020). Further cancer immunological database search verified that the 15 hub genes are mainly related to neutrophils, dendritic cells, and macrophages, which belong to innate immunity. They have a significant correlation with the prognostic outcome at different degrees and may stand for potential mechanical elucidation and even novel drug discovery (e.g., natural product drugs) (Gupta et al., 2019; Sun et al., 2020).

Lung cancer has been reported to be closely related to apoptosis and autophagy. Apoptosis serves an important role in the process of cell life. Most cancer cells have the properties of inhibiting apoptosis program so as to gain immortality (Hanahan and Weinberg, 2011). For example, a recent study found that naproxen inhibited the formation of spontaneous lung adenocarcinoma in Kras-mutant mice by significantly increasing the apoptosis of cancer cells (Kumar et al., 2021). It was believed that promoting the apoptosis of senescent cells or cancer cells is one of the main forms of anti-cancer (Pentimalli et al., 2018). In this study, Bcl-2 and Bcl-xl, which are generally highly expressed in cancer cells (Yang et al., 2019; Tanimura et al., 2021), were detected for their anti-apoptotic properties. Bcl-xl was not remarkably upregulated in the model group compared to the control group, which may lack more samples and inhibitor rescue experiments. Future studies are warranted to increase the sample volume for further verification and increase inhibitor experiments for further exploration of downstream pathways.

CONCLUSION

This study confirmed that YFSJ inhibits tumor growth and prolongs survival time by promoting tumor cell apoptosis, inhibiting tumor cell autophagy, which is consistent with the results of the previous research of our research team (Zhang X et al., 2020); thereby providing a reference for its further clinical application. Additionally, due to objective reasons, this study lacks more samples and inhibitor rescue experiments. Future studies are warranted to increase the sample volume for further verification and increase inhibitor experiments for further exploration of downstream pathways.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by the Animal Use and Management Institutional Committee of the Chinese Academy of Chinese Medical Sciences.

AUTHOR CONTRIBUTIONS

HY performed the network pharmacologic analysis, Western blot, and composed the paper. QG designed the framework, composed the part of “Method” and reviewed the paper. HY and QG have contributed equally to this work and share first authorship. JW and LZ performed the TEM detection. LS and WL helped design the research and checked mistakes. JW and LL conducted the whole research theme. All authors reviewed and approved the final manuscript.
ACKNOWLEDGMENTS

We thank the Openbiox community and hiplo team (https://hiplot.com.cn) for providing technical assistance and valuable tools for data analysis and visualization.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.851554/full#supplementary-material

REFERENCES

Alam, S., Mohammad, T., Padder, R. A., Hassan, M. I., and Husain, M. (2022). Research Funds for the Central public welfare research institutes Science Foundation of China (NO: 82074098, 82104480); the Medicine (No: ZYYCXTD-C-202002); the National Natural Science Foundation of China (No: 82074098, 82104480); the National Key Research and Development Program of China (2020YFA0908000); the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (No: ZYYCXTD-C-202002); the National Natural Science Foundation of China (NO: 82074098, 82104480); the CACMS Innovation Fund (NO: CI 2021A05101); Fundamental Research Funds for the Central public welfare research institutes (NO: ZZ15-ND-10, ZZ14-ND-010, ZZ14-YQ-050, ZZ14-YQ-060).

Hirsch, F. R., Suda, K., Wiens, J., and Bunn, P. A. (2016). New and Emerging Targeted Treatments in Advanced Non-small-cell Lung Cancer. Lancet 388 (10048), 1012–1024. doi:10.1016/S0140-6736(16)31473-8

Hopkins, A. L. (2007). Network Pharmacology. Nat. Biotechnol. 25 (10), 1110–1111. doi:10.1038/nbt1007-1110

Hopkins, A. L. (2008). Network Pharmacology: the Next Paradigm in Drug Discovery. Nat. Chem. Biol. 4 (11), 682–690. doi:10.1038/nchembio.118

Huang, C. Y., Hsu, I. H., Chen, C. Y., Chang, G. C., Chang, H. W., Hung, Y. M., et al. (2020). Inhibition of Alternative Cancer Cell Metabolism of EGF Receptor Mutated Non-small Cell Lung Cancer Serves as a Potential Therapeutic Strategy. Cancers (Basel) 12 (1). doi:10.3390/cancers12010018

Jacoby, J. J., Erez, B., Koshunova, M. V., Williams, R. R., Furutani, K., Takahashi, O., et al. (2010). Treatment with HIF-1alpha Antagonist PX-247 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice. J. Thorac. Oncol. 5 (7), 940–949. doi:10.1097/JTO.0b013e3181cd211f

Kafalti, L., Kourtzelis, I., Schulte-Schrepping, J., Li, X., Hatzioannou, A., Grinenko, T., et al. (2020). Innate Immune Training of Granulopoiesis Promotes Antitumor Activity. Cell 183 (3), 771–e127. doi:10.1016/j.cell.2020.09.058

Kanehsa, M., and Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28 (1), 27–30. doi:10.1093/nar/28.1.27

Kim, C. G., Kim, K. H., Pyo, H. K., Xin, C. F., Hong, M. H., Ahn, B. C., et al. (2019). Hyperprogressive Disease during PD-1/pd-L1 Blockade in Patients with Non-small-cell Lung Cancer. Ann. Oncol. 30 (7), 1104–1113. doi:10.1093/annonc/mdz123

Kim, Y., Chongviriyapan, N., Liu, C., Russell, R. M., and Wang, X. D. (2006). Combined Antioxidant (Beta-carotene, Alpha-Tocopherol and Ascorbic Acid) Supplementation Increases the Levels of Lung Retinoic Acid and Inhibits the Activation of Mitogen-Activated Protein Kinase in the Ferret Lung Cancer Model. Carcigenesis 27 (7), 1410–1419. doi:10.1093/carcin/bgi340

Kumar, G., Madka, V., Singh, A., Farooqui, M., Stratton, N., Lightfoot, S., et al. (2021). Naxpin Inhibits Spontaneous Lung Adenocarcinoma Formation in KrasG12V Mice. Neoplasia 23 (6), 574–583. doi:10.1016/j.neo.2021.05.010

Lai, G., Guo, Y., Chen, D., Tang, X., Shuai, O., Yong, T., et al. (2019). Alcohol Extracts from Ganoderma Lucidum Delay the Progress of Alzheimer’s Disease by Regulating DNA Methylation in Rodents. Front. Pharmacol. 10, 272. doi:10.3389/fphar.2019.00272

Lawson, K. A., Sousa, C. M., Zhang, X., Kim, E., Akthar, R., Caumanns, J. J., et al. (2020). Functional Genomic Landscape of Cancer-Intrinsic Evasion of Killing by T Cells. Nature 586 (7827), 120–126. doi:10.1038/s41586-020-2746-2

Lee, E. F., Smith, N. A., Soares da Costa, T. P., Meftahi, N., Yao, S., Harris, T. J., et al. (2019). Structural Insights into BCL2 Pro-survival Protein Interactions with the Key Autophagy Regulator BECN1 Following Phosphorylation by STK4/MST1. Autophagy 15 (5), 785–795. doi:10.1080/15548627.2018.1564557

Li, F., Ng, W. L., Luster, T. A., Hu, H., Svidersky, V. O., Dowling, C. M., et al. (2020). Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non-small Lung Cell Cancer. Cancer Res. 80 (17), 3556–3567. doi:10.1158/0008-5472.CAN-19-3782

Li, J., Miao, B., Wang, S., Dong, W., Xu, H., Si, C., et al. (2022). Hiplo: A Comprehensive and Easy-to-Use Web Service Boosting Publication-Ready Biomedical Data Visualization. bioRxiv. doi:10.1101/2020.03.16.484681

Yang et al. Anti-Lung Cancer Mechanism

FUNDING

The study was funded by the Natural Science Foundation of Guangdong Province (No: 2018B030311023); the National Key Research and Development Program of China (2020YFA0908000); the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (No: ZYYCXTD-C-202002); the National Natural Science Foundation of China (NO: 82074098, 82104480); the CACMS Innovation Fund (NO: CI 2021A05101); Fundamental Research Funds for the Central public welfare research institutes (NO: ZZ15-ND-10, ZZ14-ND-010, ZZ14-YQ-050, ZZ14-YQ-060).

Amberger, J. S., Bocchini, C. A., Scott, A. F., and Hamosh, A. (2019). OMIM.org: Frontiers in Pharmacology | www.frontiersin.org May 2022 | Volume 13 | Article 851554
Li, S., and Zhang, B. (2013). Traditional Chinese Medicine Network Pharmacology: Theory, Methodology and Application. Chin. J. Nat. Med. 11 (2), 110–120. doi:10.1007/s11588-013-0367-0

Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J. S., et al. (2017). TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 77 (21), e108–e110. doi:10.1158/0008-5472.Can-17-0307

Li, X., Chu, S., Lin, M., Gao, Y., Liu, Y., Yang, S., et al. (2020). Anticancer Property of Ginsenoside Rh2 from Ginseng. Eur. J. Med. Chem. 203, 112627. doi:10.1016/j.ejmech.2020.112627

Li, Z., Wang, Y., Wu, L., Dong, Y., Zhang, J., Chen, F., et al. (2019). Apurinic Endonuclease 1 Promotes the Cisplatin Resistance of Lung Cancer Cells by Inducing Parkin-mediated Mitophagy. Oncol. Rep. 42 (6), 2245–2254. doi:10.3892/or.2019.7345

Liu, Z., Shah, N., Marshall, K. L., Sprowls, S. A., Saralkar, P., Mohammad, A., et al. (2021). Overcoming the Acquired Resistance to Gefitinib in Lung Cancer Brain Metastasis In Vitro and In Vivo. Arch. Toxicol. 95, 3575–3587. doi:10.1007/s00204-021-03147-4

Lou, J. S., Yan, L., Bi, C. W., Chan, G. K. W., Wu, Q. Y., Liu, Y. L., et al. (2016). Yu Ping Feng Reverses Cisplatin-Induced Multi-Drug Resistance in Lung Cancer Cells via Regulating Drug Transporters and p62/TRAFA6 Signalling. Sci. Rep. 6, 31926. doi:10.1038/srep31926

Ma, H., He, Z., Chen, J., Zhang, X., and Song, P. (2021). Identifying of Biomarkers Associated with Gastric Cancer Based on 11 Topological Analysis Methods of CytoHubba. Sci. Rep. 11 (1), 1331. doi:10.1038/s41598-020-79235-9

Pentimalli, F., Forte, I., M. E., Esposito, L., Indovina, P., Iannuzzi, C. A., Alfano, L., et al. (2018). RB2/p130 Is a Direct AKT Target and Is Required to Induce Apoptosis upon AKT Inhibition in Lung Cancer and Mesothelioma Cell Lines. Oncogene 37 (27), 3657–3671. doi:10.1038/s41388-018-02143-3

Piñero, J., Ramirez-Anguita, J. M., Saich-Pitarach, J., Ronzano, F., Centeno, E., Sanz, F., et al. (2020). The DisGeNET Knowledge Platform for Disease Genomics: 2019 Update. Nucleic Acids Res. 48, D845–D855. doi:10.1093/nar/gkz1021

Priem, B., van Leent, M. T. M., Teunissen, A. J. P., Willemsen, L., et al. (2020). Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition. Cell 183 (3), 786–e197. doi:10.1016/j.cell.2020.09.059

Scarlatti, F., Maffei, R., Beau, I., Codogno, P., and Ghidoni, R. (2008). Role of Non-canonical Beclin 1-independent Autophagy in Cell Death Induced by Resveratrol in Human Breast Cancer Cells. Cell Death Differ 15 (8), 1318–1329. doi:10.1038/cdd.2008.31

Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., et al. (2003). CytoCasp: a Software Environment for Integrated Models of Molecular Interaction Networks. Genome Res. 13 (11), 2498–2504. doi:10.1101/gr.1239303

Smith, D. M., Patel, S., Raffoul, F., Haller, E., Mills, G. B., and Nanjundan, M. (2018). TISSMO: Syngeneic Mouse Tumor Database to Model Tumor Immunity and Immunotherapy Response. Nucleic Acids Res. 50, D1391–D1397. doi:10.1093/nar/gkbab04

Sun, W., Han, X., Wu, S., Wu, J., Yang, S., and Li, X. (2020). Unexpected Mechanism of Colitis Amelioration by Artesunate, a Natural Product from Traditional Chinese Medicine Treatment Based on Yiqi Huatan Method: a Multi-Target Anticancer Therapies: from Computational Models to Clinical Research of Traditional Chinese Medicine on Improving Median Survival of Elderly Patients with Non-small Cell Lung Cancer Treated by the Traditional Chinese Medicine Network Pharmacology: Yang et al. Anti-Lung Cancer Mechanism

Tanimura, K., Yamada, T., Horinaka, M., Katayama, Y., Fukui, S., Morimoto, K., et al. (2021). Inhibition of C-Jun N-Terminal Kinase Signaling Increased Apoptosis and Prevented the Emergence of ALK-TKI-Tolerant Cells in ALK-Rearranged Non-small Cell Lung Cancer. Cancer Lett. 522, 119–128. doi:10.1016/j.canlet.2021.09.018

Teng, L., Wang, K., Chen, W., Wang, Y. S., and Bi, L. (2020). HYR-2 Plays an Anti-lung Cancer Role by Regulating PD-1 and Akkermansia Muciniphila. Pharmaco. Res. 160, 105086. doi:10.1016/j.phrs.2020.105086

Tsay, A. H., Steir, P. M., Youssef, B. B., and Khuri, F. R. (2021). Locally Advanced Lung Cancer. CA A Cancer J. Clin. 71, 461–465. doi:10.3322/caac.21698

Wang, F., Tian, X., Ma, S., Gong, Y., and Xie, C. (2018). Establishment and Confirmation of GFP-Labelled Orthotopic Lewis Lung Cancer Mouse Model. Med. J. Wuhan Univ. 39 (5), 689–778

Wang, J., Wu, Q., Ding, L., Song, S., Li, Y., Shi, L., et al. (2021a). Therapeutic Effects and Molecular Mechanisms of Bioactive Compounds against Respiratory Diseases: Traditional Chinese Medicine Theory and High-Frequency Use. Front. Pharmacol. 12, 734450. doi:10.3389/fphar.2021.734450

Wang, Z., Zhou, C., and Yang, S. (2021b). The Roles, Controversies, and Combination Therapies of Autophagy in Lung Cancer. Cell Biol. Int. 46, 3–11. doi:10.1002/ctb.2350

Weiss, I. D., Elle, A., Dominsky, O., Smith, Y., Abraham, M., Wald, H., et al. (2015). In the hunt for Therapeutic Targets: Mimicking the Growth, Metastasis, and Stomatal Associations of Early-Stage Lung Cancer Using a Novel Orthotopic Animal Model. J. Thorac. Oncol. 10 (1), 46–58. doi:10.1097/doi.0000000000000367

Whirl-Carrillo, M., Huddart, R., Gong, L., Sangkhul, K., Thorn, C. F., Whaley, R., et al. (2021). An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin. Pharmac. Ther. 110, 563–572. doi:10.1002/cpt.2350

Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., et al. (2018). DrugBank 5.0: a Major Update to the DrugBank Database for 2018. Nucleic Acids Res. 46, D1074–D1082. doi:10.1093/nar/gkx1037

Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabási, A. L., and Vidal, M. (2007). Human Protein Interaction Network Construction and Analysis. Proc. Natl. Acad. Sci. USA 104 (21), 10226–10231. doi:10.1073/pnas.0609581104
Multicenter, Clinically Prospective Cohort Study. *World Chin. Medicine* 9 (7), 833–844. doi:10.3969/j.issn.1673-7202

Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., et al. (2019). Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets. *Nat. Commun.* 10 (1), 1523. doi:10.1038/s41467-019-09234-6

Zhou, Y., Zhang, Y., Lian, X., Li, F., Wang, C., Zhu, F., et al. (2021). Therapeutic Target Database Update 2022: Facilitating Drug Discovery with Enriched Comparative Data of Targeted Agents. *Nucleic Acids Res.* 50, D1398–D1407. doi:10.1093/nar/gkab953

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yang, Guo, Wu, Zhong, Sun, Liu, Wang and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.